 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Protalix BioTherapeutics
PLX
conference date: November 14, 2024 @ 5:30 AM Pacific Time
Protalix Undervalued On CHMP Recommendation Of PRX-102 For Fabry Disease [Feb. 26, 2023 @ Seeking Alpha]
Protalix Should Go Higher If FDA Approves Fabry Disease Therapy [June 4, 2020 @ Seeking Alpha]
FDA Okays Phase 3 Study of PRX-102 for Fabry Disease [November 16, 2015]
Protalix Positive Preclinical Results for NASH [October 5, 2015]
Protalix Positive Interim Phase I/II Data for PRX-102 [Jan. 8, 2015]
| 2024 | |||
| Protalix Q1 2024 |
Protalix Q2 2024 |
Protalix Q3 2024 |
|
| May 10, 2024 | Aug. 14, 2024 | Nov. 14, 2024 | |
| 2023 | |||
| Protalix Q1 2023 |
Protalix Q2 2023 |
Protalix Q3 2023 |
Protalix Q4 2023 |
| May 4, 2023 | Aug. 7, 2023 | Nov. 6, 2023 | Mar. 14, 2024 |
| 2022 | |||
| Protalix Q1 2022 |
Protalix Q2 2022 |
Protalix Q3 2022 |
Protalix Q4 2022 |
| May 16, 2022 | Aug. 15, 2022 | Nov. 14, 2022 | Feb. 27, 2023 |
| 2021 | |||
| Protalix Q1 2021 |
Protalix Q2 2021 |
Protalix Q3 2021 |
Protalix Q4 2021 |
| May 14, 2021 | Aug. 16, 2021 | Nov. 15, 2021 | March 31, 2022 |
| 2020 | |||
| Protalix Q1 2020 |
Protalix Q2 2020 |
Protalix Q3 2020 |
Protalix Q4 2020 |
| June 1, 2020 | Aug. 10, 2020 | Oct. 29, 2020 | March 30, 2021 |
| 2019 | |||
| Protalix Q1 2019 |
Protalix Q2 2019 |
Protalix Q3 2019 |
Protalix Q4 2019 |
| May 6, 2019 | August 8, 2019 | Nov. 7, 2019 | Mar. 12, 2020 |
2018 |
|||
| Protalix Q4 2018 |
|||
May 9, 2018 |
Aug. 9, 2018 |
Nov. 7, 2018 |
Mar. 14, 2019 |
2017 |
|||
May 10, 2017 |
August 9, 2017 |
Nov. 8, 2017 |
March 6, 2018 |
2016 |
|||
05/09/2016 |
08/08/2016 |
11/09/2016 |
03/16/2017 |
2015 |
|||
05/07/2015 |
08/10/2015 |
11/09/2015 |
03/08/2016 |
Protalix BioTherapeutics (PLX) is a biotechnology company making proprietary recombinant therapeutic proteins with its ProCellEx plant cell based protein expression system.
Protalix does not currently hold quarterly conference calls for analysts. It is based in Israel, but registered in Florida and files with the SEC.
Protalix BioTherapeutics web site
Protalix investor relations page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CLDX |
| CTDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is financial journalism, not advice. These notes may also be the basis for my Seeking Alpha articles.
Copyright 2024 William P. Meyers